国产亚洲欧美日韩俺去了,人妻无码久久精品,亚洲人成影院在线观看,亚洲AV永久无码精品表情包

美國B(niǎo)ioVascular Inc
BioVascular公司是一家私人持股公司，開(kāi)發(fā)生物技術(shù)藥物和設備的控制內膜增生與血管有關(guān)的程序和控制的危險因素與心血管發(fā)病率和死亡率。BioVascular的主導產(chǎn)品， saratin ，是一種多肽生產(chǎn)中酵母重組手段。該產(chǎn)品是授權默克制藥公司于2005年。 BioVascular開(kāi)始人體臨床試驗的saratin血液透析移植準入和在2006年年底將開(kāi)始人體試驗治療周?chē)鷦?dòng)脈移植在2007年年初。

BioVascular的第二個(gè)產(chǎn)品利用了一種新型機制，減少了最近界定心血管危險因素。該產(chǎn)品將進(jìn)入人體試驗階段在2007年年中。
BioVascular Inc. is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality.

BioVascular's lead product, saratin, is a polypeptide produced by recombinant means in yeast. This product was licensed from Merck, KGaA in 2005. BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006 and will begin human trials in the treatment of peripheral artery grafts in early 2007.

BioVascular’s second product utilizes a novel mechanism for reduction of a recently defined cardiovascular risk factor. This product will enter human studies in mid 2007.